Gender | Cancer sites (ICD 10 code) | Expected number of new cases, irrespective of HPV status | HPV prevalence by site (%) | Expected number of new cases attributable to HPV | Prevalence of HPV 16/18 in HPV-positive cancers (%) | Expected number of new cancer cases attributable to HPV 16/18 | Prevalence of HPV 6/11 in HPV-positive warts (%) | Expected number of new cancer cases attributable to HPV 6/11 |
---|---|---|---|---|---|---|---|---|
Male | Head and neckb | 67,354 | 14,098 | 12,707 | ||||
Anus (C21) | 2,162 | 84.2 | 1,821 | 87.1/6.2 | 1,699 | |||
Penis (C60) | 3,178 | 46.7 | 1,484 | 60.2/13.4 | 1,091 | |||
Genital warts | 380,961 | 85.5 | 325,722 | |||||
Female | Cervical cancer | 30,517 | - | - | 59.2/17.0 | 23,254 | ||
Vaginal | 1,869 | 69.9 | 1,306 | 76.8/10.9 | 1,146 | |||
Vulvar | 7,384 | 40.4 | 2,983 | 79.7/10.9 | 2,702 | |||
Anus (C21) | 3,727 | 84.3 | 3,141 | 87.1/6.2 | 2,929 | |||
Head and neck | 13,448 | 2,715 | 2,531 | |||||
Genital warts | 337,963 | 85.5 | 288,959 |